Table 2 Participants, grouping according to Chronic Kidney Disease (CKD) stages, renal diagnoses, co-morbidity, demographic and laboratory data
All patients (n = 535) | CKD stage 2 – 3* GFR range 31–69 (n = 54) | CKD stage 4** GFR range 15–29 (n = 87) | CKD stage 5** GFR range 2–14 (n = 394) | Controls* (n = 55) | |
|---|---|---|---|---|---|
Age, M (SD) | 61 (15) | 47 (11.2) | 62 (15.7) | 62 (14.4) | 48 (10.6) |
Females, n (%) | 175 (33) | 22 (41) | 35 (40) | 118 (30) | 22 (40) |
BMI, Md (IQR) | 25 (22–28) | 25 (22–28) | 25 (23–28) | 25 (22–28) | 24 (22–27) |
MAP, M (SD) | 101 (15.4) | 96 (12.8) | 94 (13.4) | 103 (5.6) | 88 (10.4) |
GFR, ml/min/1.73 m²§, M (SD) | 15 (16) | 60 (6.6) | 19 (3.1) | 8 (3) | 99 (12) |
Hb, g/L, M (SD) | 115 (17) | 136 (14.2) | 122 (12.6) | 111 (15.6) | 142 (11.5) |
p-Albumin,g/L, M (SD) | 34 (5.5) | 38 (3.6) | 36 (4.4) | 33 (5.6) | 40 (2.8) |
p-Phosphate, mmol/L, M (SD) | 1.8 (0.6) | 1.1 (0.2) | 1.4 (0.3) | 2.0 (0.6) | 1.1 (0.2) |
PTH, ng/L, Md (IQR) | 160 (76–303) | 46 (35–56) | 146 (91–204) | 201 (103–345) | 43 (38–53) |
CRP, mg/L, Md (IQR) | 5 (4–18) | 2.4 (1–4.4) | 4 (1.6–8.9) | 6 (5–23) | 0.89 (0.5–2.3) |
CRP = 5–10 mg/L, n (%) | 182 (34) | 5 (9) | 17 (20) | 160 (41) | 2 (4) |
CRP = >10 mg/L, n (%) | 163 (30) | 4 (7) | 13 (15) | 146 (37) | 3 (5) |
n, (%) | |||||
Renal vascular disease | 115 (22) | 1 (2) | 22 (25) | 92 (23) | |
Primary glomerulonephritis | 95 (18) | 18 (33) | 12 (13) | 65 (17) | |
Familial, hereditary renal disease | 58 (11) | 12 (20) | 6 (7) | 40 (10) | |
Secondary glomerular systemic diseasesa | 46 (9) | 2 (4) | 5 (6) | 39 (10) | |
Other renal diagnose | 101 (19) | 13 (24) | 20 (23) | 68 (17) | |
CVD history b | 264 (49) | 7 (13) | 49 (56) | 208 (53) | |
Diabetes history c | 158 (30) | 11 (20) | 40 (46) | 107 (27) | |
Other co-morbidityd | 119 (22) | 2 (4) | 22 (25) | 95 (24) |